Enfortumab Vedotin-Related Skin Toxicities: Insights From Clinical and Histopathological Analysis.
1/5 보강
Enfortumab vedotin (EV), targeting Nectin-4, is effective in advanced urothelial carcinoma but frequently causes skin toxicities.
APA
Kuma Y, Kido-Nakahara M, et al. (2025). Enfortumab Vedotin-Related Skin Toxicities: Insights From Clinical and Histopathological Analysis.. The Journal of dermatology, 52(10), 1584-1588. https://doi.org/10.1111/1346-8138.17901
MLA
Kuma Y, et al.. "Enfortumab Vedotin-Related Skin Toxicities: Insights From Clinical and Histopathological Analysis.." The Journal of dermatology, vol. 52, no. 10, 2025, pp. 1584-1588.
PMID
41100408 ↗
Abstract 한글 요약
Enfortumab vedotin (EV), targeting Nectin-4, is effective in advanced urothelial carcinoma but frequently causes skin toxicities. This study examined the possible contribution of prior immune checkpoint inhibitor (ICI) therapy and higher EV doses to EV-related skin toxicity (EVST) development. Histopathological findings suggested both direct keratinocyte damage and immune-mediated mechanisms. These insights may improve clinical management of EVST.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- A Phase I Study of Hydroxychloroquine and Suba-Itraconazole in Men with Biochemical Relapse of Prostate Cancer (HITMAN-PC): Dose Escalation Results.
- Self-management of male urinary symptoms: qualitative findings from a primary care trial.
- Clinical and Liquid Biomarkers of 20-Year Prostate Cancer Risk in Men Aged 45 to 70 Years.
- Diagnostic accuracy of Ga-PSMA PET/CT versus multiparametric MRI for preoperative pelvic invasion in the patients with prostate cancer.
- Association of patient health education with the postoperative health related quality of life in low- intermediate recurrence risk differentiated thyroid cancer patients.
- Early local immune activation following intra-operative radiotherapy in human breast tissue.